Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 173.28 Million CHF | -21.53% |
| 2022 | 220.84 Million CHF | -10.68% |
| 2021 | 247.26 Million CHF | 7.6% |
| 2020 | 229.79 Million CHF | 3.76% |
| 2019 | 221.46 Million CHF | -21.4% |
| 2018 | 281.75 Million CHF | -19.77% |
| 2017 | 351.16 Million CHF | 7.14% |
| 2016 | 327.75 Million CHF | -17.8% |
| 2015 | 398.73 Million CHF | 54.92% |
| 2014 | 257.37 Million CHF | -14.14% |
| 2013 | 299.75 Million CHF | -20.14% |
| 2012 | 375.34 Million CHF | 58.31% |
| 2011 | 237.09 Million CHF | -25.1% |
| 2010 | 316.54 Million CHF | 53.21% |
| 2009 | 206.6 Million CHF | -37.03% |
| 2008 | 328.12 Million CHF | -28.89% |
| 2007 | 461.44 Million CHF | 127.22% |
| 2006 | 203.08 Million CHF | -20.53% |
| 2005 | 255.56 Million CHF | 10.74% |
| 2004 | 230.78 Million CHF | 115.64% |
| 2003 | 107.01 Million CHF | -28.9% |
| 2002 | 150.51 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 188.66 Million CHF | 0.0% |
| 2023 Q4 | 173.28 Million CHF | 0.0% |
| 2023 Q2 | 230.03 Million CHF | 0.0% |
| 2023 FY | 173.28 Million CHF | -21.53% |
| 2022 FY | 220.84 Million CHF | -10.68% |
| 2022 Q4 | 220.84 Million CHF | 0.0% |
| 2022 Q2 | 236.07 Million CHF | 0.0% |
| 2021 FY | 247.26 Million CHF | 7.6% |
| 2021 Q2 | 227.17 Million CHF | 0.0% |
| 2021 Q4 | 247.26 Million CHF | 0.0% |
| 2020 Q4 | 229.79 Million CHF | 0.0% |
| 2020 Q2 | 197.05 Million CHF | 0.0% |
| 2020 FY | 229.79 Million CHF | 3.76% |
| 2019 Q2 | 235.64 Million CHF | 0.0% |
| 2019 FY | 221.46 Million CHF | -21.4% |
| 2019 Q4 | 221.46 Million CHF | 0.0% |
| 2018 FY | 281.75 Million CHF | -19.77% |
| 2018 Q4 | 281.75 Million CHF | 0.0% |
| 2018 Q2 | 305.1 Million CHF | 0.0% |
| 2017 Q4 | 351.16 Million CHF | 0.0% |
| 2017 Q2 | 293.89 Million CHF | 0.0% |
| 2017 FY | 351.16 Million CHF | 7.14% |
| 2016 Q4 | 327.75 Million CHF | 0.0% |
| 2016 Q2 | 345.65 Million CHF | 0.0% |
| 2016 FY | 327.75 Million CHF | -17.8% |
| 2015 Q2 | 248.87 Million CHF | 0.0% |
| 2015 Q4 | 398.73 Million CHF | 0.0% |
| 2015 FY | 398.73 Million CHF | 54.92% |
| 2014 FY | 257.37 Million CHF | -14.14% |
| 2014 Q4 | 257.37 Million CHF | 0.0% |
| 2014 Q2 | 274.33 Million CHF | 0.0% |
| 2013 Q2 | 290.27 Million CHF | 0.0% |
| 2013 FY | 299.75 Million CHF | -20.14% |
| 2013 Q4 | 299.75 Million CHF | 0.0% |
| 2012 Q2 | 190.41 Million CHF | 0.0% |
| 2012 FY | 375.34 Million CHF | 58.31% |
| 2012 Q4 | 375.34 Million CHF | 0.0% |
| 2011 FY | 237.09 Million CHF | -25.1% |
| 2011 Q2 | 279.01 Million CHF | 0.0% |
| 2011 Q4 | 237.09 Million CHF | 0.0% |
| 2010 Q2 | 229.01 Million CHF | 0.0% |
| 2010 FY | 316.54 Million CHF | 53.21% |
| 2010 Q4 | 316.54 Million CHF | 0.0% |
| 2009 Q4 | 206.6 Million CHF | 0.0% |
| 2009 FY | 206.6 Million CHF | -37.03% |
| 2008 FY | 328.12 Million CHF | -28.89% |
| 2007 FY | 461.44 Million CHF | 127.22% |
| 2006 FY | 203.08 Million CHF | -20.53% |
| 2005 FY | 255.56 Million CHF | 10.74% |
| 2004 FY | 230.78 Million CHF | 115.64% |
| 2003 FY | 107.01 Million CHF | -28.9% |
| 2002 FY | 150.51 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Addex Therapeutics Ltd | 4.64 Million CHF | -3633.842% |
| BB Biotech AG | 2.63 Billion CHF | 93.429% |
| Evolva Holding SA | 9.82 Million CHF | -1663.181% |
| Idorsia Ltd | 499.99 Million CHF | 65.342% |
| Kuros Biosciences AG | 75.9 Million CHF | -128.294% |
| Molecular Partners AG | 198.35 Million CHF | 12.636% |
| Relief Therapeutics Holding AG | 76.39 Million CHF | -126.848% |
| Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | -58.069% |